INFU vs. KIDS, TMCI, DCTH, CLPT, ZIMV, SMLR, NPCE, NYXH, TCMD, and NNOX
Should you be buying InfuSystem stock or one of its competitors? The main competitors of InfuSystem include OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Delcath Systems (DCTH), ClearPoint Neuro (CLPT), ZimVie (ZIMV), Semler Scientific (SMLR), NeuroPace (NPCE), Nyxoah (NYXH), Tactile Systems Technology (TCMD), and Nano-X Imaging (NNOX). These companies are all part of the "medical equipment" industry.
InfuSystem vs.
OrthoPediatrics (NASDAQ:KIDS) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.
69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 31.8% of OrthoPediatrics shares are owned by insiders. Comparatively, 10.2% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
InfuSystem has a net margin of 1.12% compared to OrthoPediatrics' net margin of -15.00%. InfuSystem's return on equity of 2.78% beat OrthoPediatrics' return on equity.
InfuSystem has lower revenue, but higher earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
OrthoPediatrics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.
In the previous week, InfuSystem had 2 more articles in the media than OrthoPediatrics. MarketBeat recorded 5 mentions for InfuSystem and 3 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.47 beat InfuSystem's score of -0.04 indicating that OrthoPediatrics is being referred to more favorably in the media.
OrthoPediatrics presently has a consensus target price of $39.00, indicating a potential upside of 69.20%. InfuSystem has a consensus target price of $13.00, indicating a potential upside of 100.00%. Given InfuSystem's stronger consensus rating and higher probable upside, analysts clearly believe InfuSystem is more favorable than OrthoPediatrics.
OrthoPediatrics received 305 more outperform votes than InfuSystem when rated by MarketBeat users. However, 100.00% of users gave InfuSystem an outperform vote while only 64.26% of users gave OrthoPediatrics an outperform vote.
Summary
InfuSystem beats OrthoPediatrics on 13 of the 19 factors compared between the two stocks.
Get InfuSystem News Delivered to You Automatically
Sign up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InfuSystem Competitors List
Related Companies and Tools
This page (NYSE:INFU) was last updated on 3/4/2025 by MarketBeat.com Staff
Free INFU Stock Alerts